WEST PHARMACEUTICAL SERVICES INC
No SEC Form 4 filings for $WST in the last 30 days.
Conestoga Capital Advisors’ Q2 2026 investor letter says small-cap growth led markets, with the Russell 2000 Growth Index up 25.7% in Q2. The letter highlights West Pharmaceutical Services (NYSE:WST), noting a higher stock after another quarter of broad-based growth. It cites 15% organic revenue growth and a reinstated long-term outlook tied to biologics and GLP-1 demand.
West Pharmaceutical Services reported higher Q2 2026 sales and earnings, raised its full-year 2026 revenue outlook, completed a US$454.28 million share repurchase, and kept its US$0.22 quarterly dividend. It also expanded a Daikyo Seiko distribution deal via new 10-year agreements, granting West exclusivity outside Japan and expanding Daikyo’s role in Japan.
West Pharmaceutical Services (WST) said it signed a decade-long distribution agreement with Daikyo that extends beyond Japan, according to the company. The deal covers distribution of West’s products in additional markets over the 10-year term, which could affect future revenue and regional sales mix.
Over the past 7 days, alphai's AI scored 1 news story mentioning WST (WEST PHARMACEUTICAL SERVICES INC). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent WST coverage spans earnings, financial news and market movers.
The article frames WST as benefiting from sustained biologics and GLP-1-related packaging demand, with management reinstating a favorable long-term growth outlook.
Raised 2026 guidance plus a longer Daikyo distribution expansion is a near-term revenue visibility positive, but valuation and execution risk remain.
A long-duration distribution agreement can support revenue visibility and strengthen distribution reach, but the article body provides no deal terms.
Raised 2026 growth and margin outlook tied to HVP components, Annex 1 upgrade demand, and SmartDose divestiture tailwind.
The article suggests a broad risk-off move for healthcare suppliers, not a new WST event.
alphai scores every news story that mentions WST with an AI model for sentiment and relevance, and aggregates insider trades from WEST PHARMACEUTICAL SERVICES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Conestoga Capital Advisors’ Q2 2026 investor letter says small-cap growth led markets, with the Russell 2000 Growth Index up 25.7% in Q2. The letter highlights West Pharmaceutical Services (NYSE:WST), noting a higher stock after another quarter of broad-based growth. It cites 15% organic revenue growth and a reinstated long-term outlook tied to biologics and GLP-1 demand.
4 min readWest Pharmaceutical Services reported higher Q2 2026 sales and earnings, raised its full-year 2026 revenue outlook, completed a US$454.28 million share repurchase, and kept its US$0.22 quarterly dividend. It also expanded a Daikyo Seiko distribution deal via new 10-year agreements, granting West exclusivity outside Japan and expanding Daikyo’s role in Japan.
5 min readWest Pharmaceutical Services (WST) said it signed a decade-long distribution agreement with Daikyo that extends beyond Japan, according to the company. The deal covers distribution of West’s products in additional markets over the 10-year term, which could affect future revenue and regional sales mix.
1 min readWest Pharmaceutical Services reported Q2 2026 results driven by 16% organic growth in Proprietary Products, including a 29% rise in Biologics. High-Value Product components rose to 49% of revenue. Full-year 2026 organic growth guidance was raised to 10% to 11%, with margin expansion expected. SmartDose divestiture and a May cyber incident were cited.
7 min readStocks including Hims & Hers Health (HIMS), Repligen (RGEN), West Pharmaceutical Services (WST), and 10x Genomics (TXG) fell after concerns about a rising number of uninsured patients. The article cites HCA Healthcare’s earnings report, saying a negative payer mix shift reduced its estimated pre-tax income by about $400 million in the quarter.
5 min readWest Pharmaceutical Services (NYSE:WST) reported Q2 revenue of $872 million, up 13% organically, and adjusted EPS of $2.37, up 29% year over year. The company raised its 2026 outlook to $3.345 billion-$3.38 billion revenue and adjusted EPS of $8.85-$9.05, citing strong high-value product components demand tied to biologics and GLP-1 elastomers, plus margin expansion and buybacks.
6 min readWest Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 revenue of $872.3 million, up 13.8% year on year and above market expectations by 3.5%, according to the company. Non-GAAP EPS was $2.37, 13.9% above consensus. Next-quarter revenue guidance midpoint was $827.5 million. Shares rose about 7.3% to $384.97 after results.
4 min readWest Pharmaceutical Services (WST) shares rose about 6.1% pre-open after its Q2 2026 results beat expectations. Adjusted EPS was $2.37 vs $2.08 expected, and revenue was $872.3M vs $839.75M. The company raised full-year 2026 adjusted EPS guidance to $8.85-$9.05 and gave above-consensus Q3 guidance.
3 min readWest Pharmaceutical Services (WST) reported higher Q2 net income and said it raised its Q3 and FY26 outlook, according to the company. The article cites Q2 net income of $154.0 million, or $2.15 per share, and notes shares were up in pre-market trading.
2 min readWEST PHARMACEUTICAL SERVICES INC (WST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh991q22026earningsrelease.htm EX-99.1 Document Exhibit 99.1 West Reports Second-Quarter 2026 Results Raising Full-Year Net Sales and EPS guidance Exton, PA, July 23, 2026 – West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality
4 min read
